BioMarin Pharmaceutical Inc. Files 8-K on Financials

Ticker: BMRN · Form: 8-K · Filed: Aug 4, 2025 · CIK: 1048477

Biomarin Pharmaceutical INC 8-K Filing Summary
FieldDetail
CompanyBiomarin Pharmaceutical INC (BMRN)
Form Type8-K
Filed DateAug 4, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, operations, sec-filing

Related Tickers: BMRN

TL;DR

BioMarin dropped an 8-K on Aug 4th covering financials - check it for the latest numbers.

AI Summary

BioMarin Pharmaceutical Inc. filed an 8-K on August 4, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance. The report is for the period ending August 4, 2025.

Why It Matters

This filing provides investors with crucial updates on BioMarin's financial health and operational performance, impacting investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual or immediate risks.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

What is the reporting period for this 8-K filing?

The report is dated August 4, 2025, and the 'Conformed Period of Report' is also August 4, 2025.

Where is BioMarin Pharmaceutical Inc. headquartered?

The filing lists the Principal Executive Offices at 770 Lindaro Street, San Rafael, California 94901.

What is the SEC file number for BioMarin Pharmaceutical Inc.?

The SEC file number for BioMarin Pharmaceutical Inc. is 000-26727.

What is the Standard Industrial Classification (SIC) code for BioMarin Pharmaceutical Inc.?

The SIC code listed is 2834 for Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 4, 2025 regarding BIOMARIN PHARMACEUTICAL INC (BMRN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing